AstraZeneca rolls out Movantik; Novartis nabs FDA blessing for Jadenu; Indian drugmakers start hiring pharmacy grads as sales reps;

> AstraZeneca ($AZN) said the constipation-fighting drug Movantik has been launched in the U.S.; the company announced a marketing partnership with Daiichi Sankyo on the drug earlier this month. Release

> Novartis ($NVS) won FDA approval for Jadenu, a new oral formulation of its iron-chelation med Exjade. Release

> Novo Nordisk ($NVO) is preparing to roll out its hemophilia med Novoeight, approved in 2013 but unable to make its debut till mid-April because of patent issues. Release

> Indian drugmakers are recruiting pharmacy school grads to promote new specialty drugs, to reduce the need for training and better explain complex medications to doctors. Report

> A new study in JAMA Psychiatry showed that a once-quarterly version of Johnson & Johnson's ($JNJ) Invega drug significantly delayed relapses in patients with schizophrenia. Release

> Johnson & Johnson's ($JNJ) prostate cancer med Zytiga won FDA approval for new label information highlighting data on the pill's overall survival benefits in men not yet treated with chemo. Release

And Finally... A contrarian analyst questions big sales projections on cancer immunotherapies. Report

Suggested Articles

A small group of physicians expressed little interest in new MS drugs from Novartis, Merck KGaA and Biogen but favored a repurposed therapy.

Sanofi and Regeneron recently debuted an unbranded awareness and education campaign around type 2 inflammation and its connections across conditions.

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.